Clinical trials: Advanced Solid Cancer
Colorectal Cancer, Stomach Cancer
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors…
- Conditions
- Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
- Trial name
- NCT06821048
- Testing
- Intraperitoneal infusion of FAST CEA-targeted CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Weijia Fang, MD
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Unspecified Adult Solid Tumor, Protocol Specific
17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00248521
- Testing
- alvespimycin hydrochloride
- Where
- 3 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Non Small Cell Lung Cancer, Advanced Solid Tumor
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
- Trial name
- NCT06484816
- Testing
- TGRX-1942
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Neoplasms, Neoplasms, Glandular and Epithelial
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK)…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02909452
- Testing
- Entinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Neoplasms
A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
This study will determine the maximum tolerated dose and the dose limiting toxicities (Part 1 of study) and the activity (Part 2 of study) of RO5126766 in patients with metastatic or advanced solid tumors.
- Trial name
- NCT00773526
- Testing
- RO5126766
- Where
- 3 sites in France, Spain and 1 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan
This study will characterize the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of AUY922 in adult patients with advanced solid malignancies in Japan.
- Trial name
- NCT01132625
- Testing
- AUY922
- Where
- 2 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors
The research project is testing this potential new medication for advanced solid tumours. This research project is being done to get more information about the study drug (XNW7201).
- Trial name
- NCT03901950
- Testing
- XNW7201 tablets
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Evopoint Biosciences Inc.
Anxiety, Depression
Brief CBT for Anxiety and Advanced Cancer
RATIONALE: Providing cognitive-behavioral therapy (CBT) may reduce anxiety and improve quality of life of patients with advanced cancer.
- Conditions
- Anxiety, Depression, Unspecified Adult Solid Tumor, Protocol Specific, Cancer
- Trial name
- NCT00706290
- Testing
- Brief Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Massachusetts General Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Advanced Malignant Solid Tumors
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150…
- Trial name
- NCT07566247
- Testing
- AK150
- Where
- 3 sites in China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Akeso
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Melanoma, Non Small Cell Lung Cancer
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma
- Trial name
- NCT05366478
- Testing
- Autologous tumor infiltrating lymphocytes (TILs)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Advanced Solid Tumors
Study of GS-2426 in Participants With Advanced Solid Tumors
The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors.
- Trial name
- NCT07601243
- Testing
- GS-2426
- Where
- 6 sites in United States, Spain
- Volunteers
- 174 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumors
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion study of AMG 780 in up to 62 subjects with advanced solid tumors.
- Trial name
- NCT01137552
- Testing
- AMG 780
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Amgen
Neoplasms
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
- Trial name
- NCT06311578
- Testing
- JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Advanced Solid Tumors
A Study of DXC018 in Patients With Advanced Solid Tumors
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC018 in participants…
- Trial name
- NCT07849218
- Testing
- DXC018
- Where
- 4 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Advanced Solid Tumors
A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients
In many types of human tumors, PD-L1 is highly expressed. Such high expression has often been associated with poor prognosis in cancer patients.
- Trial name
- NCT03133247
- Testing
- SHR-1316
- Where
- Australia
- Volunteers
- 37 people
- Sponsor
- Atridia Pty Ltd.
Advanced or Metastatic Solid Tumors
A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors
This is a multicenter, open-label, uncontrolled, phase I study to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ONO-4538HSC administered subcutaneously in participants with advanced or metastatic solid…
- Trial name
- NCT06548217
- Testing
- ONO-4538HSC
- Where
- 8 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.